Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 11/2012

01-11-2012 | Review

Current Advantages in the Application of Proteomics in Inflammatory Bowel Disease

Authors: Anna Vaiopoulou, Maria Gazouli, George Theodoropoulos, George Zografos

Published in: Digestive Diseases and Sciences | Issue 11/2012

Login to get access

Abstract

Since the formulation of the concept of proteomics, a plethora of proteomic technologies have been developed in order to study proteomes. In inflammatory bowel disease (IBD), several studies use proteomics to try to better understand the disease and discover molecules which can be used as biomarkers. Biomarkers should be able to be used for diagnosis, therapy and prognosis. Although several biomarkers have been discovered, few biomarkers have clinical value. In this review, we analyze and report the current use of proteomic techniques to highlight biomarkers characterizing IBD, and different stages of disease activity. We also report the biomarkers and their potential clinical value.
Literature
1.
2.
3.
Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev. 2007;59:1073–1083.PubMedCrossRef
4.
Xavier R, Podolsky DK. Commensal flora: wolf in sheep’s clothing. Gastroenterology. 2005;128:1122–1126.PubMedCrossRef
5.
Kugathasan S, Fiocchi C. Progress in basic inflammatory bowel disease research. Semin Pediatr Surg. 2007;16:146–153.PubMedCrossRef
6.
Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422–1433.PubMedCrossRef
7.
Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol Clin Biol. 2009;33:S158–S173.PubMedCrossRef
8.
Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Trans Res. 2012;159:313–325.CrossRef
9.
Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 2008;14:5115–5124.PubMedCrossRef
10.
Alex P, Gucek M, Li X. Applications of proteomics in the study of inflammatory bowel diseases: current status and future directions with available technologies. Inflamm Bowel Dis. 2009;15:616–629.PubMedCentralPubMedCrossRef
11.
Roy P, Shukla Y. Applications of proteomic techniques in cancer research. Cancer Therapy. 2008;6:841–856.
12.
Goldknopf IL. Blood-based proteomics for personalized medicine: examples from neurodegenerative disease. Expert Rev Proteomics. 2008;5:1–8.PubMedCrossRef
13.
Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics. 2005;4:409–418.PubMedCrossRef
14.
VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn. 2007;7:625–633.PubMedCrossRef
15.
Cekaite L, Hovig E, Sioud M. Protein arrays: a versatile toolbox for target identification and monitoring of patient immune responses. Methods Mol Biol. 2007;360:335–348.PubMed
16.
Hamelinck D, Zhou H, Li L, et al. Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell Proteomics. 2005;4:773–784.PubMedCrossRef
17.
Chaerkady R, Pandey A. Applications of proteomics to lab diagnosis. Annu Rev Pathol. 2008;3:485–498.PubMedCrossRef
18.
Cravatt BF, Simon GM, Yates JR 3rd. The biological impact of mass-spectrometry- based proteomics. Nature. 2007;450:991–1000.PubMedCrossRef
19.
Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452:571–579.PubMedCrossRef
20.
Gulcicek EE, Colangelo CM, McMurray W, et al. Proteomics and the analysis of proteomic data: an overview of current protein-profiling technologies. Curr Protoc Bioinformatics. 2005;13:1.PubMed
21.
Reinders J, Sickmann A. Modificomics: posttranslational modifications beyond protein phosphorylation and glycosylation. Biomol Eng. 2007;24:169–177.PubMedCrossRef
22.
Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl. 2005;44:7342–7372.PubMedCrossRef
23.
Felley-Bosco E, André M. Proteomics and chronic inflammatory bowel diseases. Pathol Res Pract. 2004;200:129–133.PubMedCrossRef
24.
Feng JT, Shang S, Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene. 2006;25:3810–3817.PubMedCrossRef
25.
Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem. 2001;70:437–473.PubMedCrossRef
26.
Hatsugai M, Kurokawa MS, Kouro T, et al. Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn’s disease. J Gastroenterol. 2010;45:488–500.PubMedCrossRef
27.
Markó L, Szigeti N, Szabó Z, et al. Potential urinary biomarkers of disease activity in Crohn’s disease. Scand J Gastroenterol. 2010;45:1440–1448.PubMedCrossRef
28.
Meuwis MA, Fillet M, Lutteri L, et al. Proteomics for prediction and characterization of response to infliximab in Crohn’s disease: a pilot study. Clin Biochem. 2008;41:960–967.PubMedCrossRef
29.
Nanni P, Parisi D, Roda G, et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom. 2007;21:4142–4148.PubMedCrossRef
30.
Subramanian V, Subramanian D, Pollok RC. Serum protein signatures determined by mass Spectrometry (SELDI-ToF) accurately distinguishes Crohn’s disease (CD) from ulcerative colitis (UC). Gastroenterology. 2008;134:196.
31.
Bertone P, Snyder M. Advances in functional protein microarray technology. FEBS J. 2005;272:5400–5411.PubMedCrossRef
32.
33.
Chen CS, Sullivan S, Anderson T, et al. Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip. Mol Cell Proteomics. 2009;8:1765–1776.PubMedCrossRef
34.
Vermeulen N, Vermeire S, Michiels G, Joossens M, Rutgeerts PJ, Bosuyt X. Protein microarray experiments for profiling of the autoimmune response in inflammatory bowel disease; identification of PHLA1. Gastroenterology. 2008;134:197.CrossRef
35.
Sullivan S, Zhu H, Cuffari C, et al. Identification and validation of serological IBD biomarkers by a novel high throughput proteomic approach using high density protein chip technology. Gastroenterology. 2006;130:A24.
36.
Kader HA, Tchernev VT, Satyaraj E, et al. Patel. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-β1, and IL-12p40 levels in Crohn’s disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol. 2005;100:414–423.PubMedCentralPubMedCrossRef
37.
Schrader M, Schulz-Knappe P. Peptidomics technologies for human body fluids. Trends Biotechnol. 2001;19:S55–S60.PubMedCrossRef
38.
Govorun VM, Ivanov VT. Proteomics and peptidomics in fundamental and applied medical studies. Bioorg Khim. 2011;37:199–215.PubMed
39.
Nanni P, Levander F, Roda G, Caponi A, James P, Roda A. A label-free nano-liquid chromatography-mass spectrometry approach for quantitative serum peptidomics in Crohn’s disease patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:3127–3136.PubMedCrossRef
40.
Ray S, Reddy PJ, Jain R, Gollapalli K, Moiyadi A, Srivastava S. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics. 2011;11:2139–2161.PubMedCrossRef
41.
Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis. 2010;28:418–423.PubMedCrossRef
42.
43.
44.
Haleem JI, Zhen X, Timothy DV. Serum and plasma proteomics. Chem Rev. 2007;107:3601–3620.CrossRef
45.
Ebert MP, Korc M, Malfertheiner P, Rocken C. Advances, challenges, and limitations in serum-proteomebased cancer diagnosis. J Proteome Res. 2006;5:19–25.PubMedCrossRef
46.
47.
Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730–734.PubMedCrossRef
48.
Dubinsky MC, Lin YC, Dutridge D, et al. Western Regional Pediatric IBD Research Alliance. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360–367.PubMedCentralPubMedCrossRef
49.
Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease. Gastroenterology. 2006;131:366–378.PubMedCrossRef
50.
Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56:1394–1403.PubMedCrossRef
51.
Vandewalle-El Khoury P, Colombel JF, Joossens S, et al. Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn’s disease patients and contributes to differential diagnosis, stratification, and prediction. Am J Gastroenterol. 2008;103:949–957.PubMedCrossRef
52.
Sakiyama T, Fujita H, Tsubouchi H. Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn’s disease. Inflamm Bowel Dis. 2008;14:310–317.PubMedCrossRef
53.
Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–665.PubMedCrossRef
54.
Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–712.PubMedCrossRef
55.
Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn’s disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10:401–405.PubMedCrossRef
56.
Wright JP, Young GO, Tigler-Wybrandi N. Predictors of acute relapse of Crohn’s disease. A laboratory and clinical study. Dig Dis Sci. 1987;32:164–170.PubMedCrossRef
57.
Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S, Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol. 1986;8:647–650.PubMedCrossRef
58.
Sachar DB, Luppescu NE, Bodian C, Shlien RD, Fabry TL, Gumaste VV. Erythrocyte sedimentation as a measure of Crohn’s disease activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol. 1990;12:643–646.PubMedCrossRef
59.
Jensen KB, Jarnum S, Koudahl G, Kristensen M. Serum orosomucoid in ulcerative colitis: its relation to clinical activity, protein loss, and turnover of albumin and IgG. Scand J Gastroenterol. 1976;11:177–183.PubMed
60.
Andre C, Descos L, Landais P, Fermanian J. Assessment of appropriate laboratory measurements to supplement the Crohn’s disease activity index. Gut. 1981;22:571–574.PubMedCrossRef
61.
Lehrke M, Konrad A, Schachinger V, et al. CXCL16 is a surrogate marker of inflammatory bowel disease. Scand J Gastroenterol. 2008;43:283–288.PubMedCrossRef
62.
Broedl UC, Schachinger V, Lingenhel A, et al. Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease. Inflamm Bowel Di. 2007;13:391–397.CrossRef
63.
Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070–1074.PubMedCrossRef
64.
Van Assche G, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288:G169–G174.PubMedCrossRef
65.
Magro F, Araujo F, Pereira P, Meireles E, Diniz-Ribeiro M, Velosom FT. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004;49:1265–1274.PubMedCrossRef
66.
van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129–135.PubMedCrossRef
67.
Stronkhorst A, Jansen J, Tytgat G, van Deventer SJH. Soluble IL-2 and TNF receptors p55 and p75 in Crohn’s disease. Gastroenterology. 1994;106:A779.
68.
Propst A, Propst T, Herold M, Vogel W, Judmaier G. Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 1995;7:1031–1036.PubMedCrossRef
69.
Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol. 1995;154:2434–2440.PubMed
70.
Crabtree JE, Juby LD, Heatley RV, Lobo AJ, Bullimore DW, Axon AT. Soluble interleukin-2 receptor in Crohn’s disease: relation of serum concentrations to disease activity. Gut. 1990;31:1033–1036.PubMedCrossRef
71.
72.
Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in Crohn’s disease. Gut. 2005;54:488–495.PubMedCrossRef
73.
Jones SC, Evans SW, Lobo AJ, Ceska M, Axon AT, Whicher JT. Serum interleukin-8 in inflammatory bowel disease. J Gastroenterol Hepatol. 1993;8:508–512.PubMedCrossRef
74.
Kucharzik T, Stoll R, Lügering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;100:452–456.PubMedCentralPubMedCrossRef
75.
Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7:460–465.PubMed
76.
Angriman I, Scarpa M, D’Incà R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63–68.PubMedCrossRef
77.
Poullis A, Foster R, Northfield TC, Mendal MA. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:675–681.PubMedCrossRef
78.
Saverymuttu SH, Peters AM, Crofton ME, et al. 111Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut. 1985;26:955–960.PubMedCrossRef
79.
Fagerhol MK, Dale I, Anderson I. Release and quantification of leukocyte derived protein (L1). Scand J Haematol. 1980;24:393–398.CrossRef
80.
Taehon K, Roseth AG, Foster R, Bjarnason I. Fecal calprotectin: a simple sensitive quantitative measure of intestinal inflammation in man. Gastroenterology. 1997;112:A1103.CrossRef
81.
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterolgy. 2000;119:15–22.CrossRef
82.
Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54:364–368.PubMedCrossRef
83.
Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190–1198.PubMedCrossRef
84.
Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:414–422.PubMedCrossRef
85.
Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847–853.PubMedCrossRef
86.
Hugot J-P, Chamaiilard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603.PubMedCrossRef
87.
Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in Nod2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–606.PubMedCrossRef
88.
Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nature Genet. 2010;42:1118–1125.PubMedCentralPubMedCrossRef
89.
Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genet. 2011;43:246–252.PubMedCentralPubMedCrossRef
90.
Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treatment in Crohn’s disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics. 2002;12:509–515.PubMedCrossRef
91.
Mascheretti S, Schreiber S. Genetic testing in Crohn disease: utility in individualizing patient management. Am J Pharmacogenomics. 2005;5:213–222.PubMedCrossRef
92.
Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol. 2004;20:318–327.PubMedCrossRef
93.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.PubMedCrossRef
94.
Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14:841–845.PubMedCrossRef
Metadata
Title
Current Advantages in the Application of Proteomics in Inflammatory Bowel Disease
Authors
Anna Vaiopoulou
Maria Gazouli
George Theodoropoulos
George Zografos
Publication date
01-11-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2291-4

Other articles of this Issue 11/2012

Digestive Diseases and Sciences 11/2012 Go to the issue

Original Article

Patients with Esophageal Motility Disorders Show Distinct Patterns Based on Axial Force Measurements

Original Article

Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders

Stanford Multidisciplinary Seminars

Acute Fulminant Hepatic Failure Associated with Parvovirus B19 Infection in an Immunocompetent Adult

Review

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan

Original Article

Diagnosis of Hereditary Hemochromatosis in the Era of Genetic Testing

Editorial

Early Diagnosis of Hepatocellular Carcinoma by MicroRNAs: Shining a Light from the Genome’s “Dark Matter”
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits